Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis

被引：12
|
作者：
Scalco, R. S. [1 ]
Voermans, N. C. [2 ]
Piercy, R. J. [3 ]
Jungbluth, H. [4 ]
Quinlivan, R. [1 ]
机构：
[1] UCL, MRC Ctr Neuromuscular Dis, London, England
[2] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, Nijmegen, Netherlands
[3] Royal Vet Coll, Comparat Neuromuscular Dis Lab, London, England
[4] Kings Coll London, IoPPN, Dept Clin & Basic Neurosci, London WC2R 2LS, England
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2016年 / 23卷 / 08期
关键词：
dantrolene; myoglobinuria; rhabdomyolysis prophylaxis; rhabdomyolysis treatment; RYR1; prophylaxis; treatment; RECURRENT EXERTIONAL RHABDOMYOLYSIS; HORSES; SODIUM; RYR1;
D O I：
10.1111/ene.13051
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E56 / E57
页数：2
相关论文
共 50 条
  • [1] Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis
    Siciliani Scalco, R.
    Voermans, N. C.
    Jungbluth, H.
    Quinlivan, R.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S38 - S38
  • [2] Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis
    Scalco, R.
    Voermans, N.
    Jungbluth, H.
    Quinlivan, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 689 - 689
  • [3] Dantrolene as a treatment option for RYR1-related rhabdomyolysis
    Scalco, R.
    Voermans, N.
    Piercy, R.
    Jungbluth, H.
    Quinlivan, R.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S136 - S136
  • [4] Symptomatic and Prophylactic Dantrolene Treatment in a Case of RYR1-Related Congenital Myopathy
    Senol, Hueseyin B.
    Polat, Ayse, I
    Aydin, Adem
    Hiz, Ayse S.
    Yis, Uluc
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2025, 28 (01) : 126 - 128
  • [5] Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis
    de Lima Silva, Elis Vanessa
    Donis, Karina Carvalho
    Camara Machado, Fabiana Rita
    Medeiros, Leonardo Simao
    de Moura Aschoff, Carlos Alberto
    Moura de Souza, Carolina Fischinger
    Poswar, Fabiano de Oliveira
    Morales Saute, Jonas Alex
    JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (06) : 1145 - 1149
  • [6] RYR1-related exertional rhabdomyolysis: Expanding spectrum and diagnostic challenges
    Gardiner, A.
    Scalco, R.
    Parton, M.
    Hanna, M.
    Pitceathly, R.
    Zanoteli, E.
    Murphy, E.
    Treves, S.
    Houlden, H.
    Wilmshurst, J.
    Straub, V.
    Hilton-Jones, D.
    Voermans, N.
    Manzur, A.
    Oflazer, R.
    Reed, U.
    Lachmann, R.
    Quinlivan, R.
    Jungbluth, H.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S257 - S258
  • [7] Neuromuscular symptoms in patients with RYR1-related malignant hyperthermia and rhabdomyolysis
    van den Bersselaar, Luuk R.
    Jungbluth, Heinz
    Kruijt, Nick
    Kamsteeg, Erik-Jan
    Fernandez-Garcia, Miguel A.
    Treves, Susan
    Riazi, Sheila
    Malagon, Ignacio
    van Eijk, Lucas T.
    van Alfen, Nens
    van Engelen, Baziel G. M.
    Scheffer, Gert-Jan
    Snoeck, Marc M. J.
    Voermans, Nicol C.
    BRAIN COMMUNICATIONS, 2022, 4 (06)
  • [8] Familial variation in phenotype in RYR1-related myalgia-rhabdomyolysis syndrome
    Witting, N.
    Solheim, T.
    Dahlqvist, J.
    Poulsen, N.
    Duno, M.
    Vissing, J.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S46 - S46
  • [9] The neuromuscular and multisystem features of RYR1-related malignant hyperthermia and rhabdomyolysis A study protocol
    van den Bersselaar, Luuk R.
    Kruijt, Nick
    Scheffer, Gert-Jan
    van Eijk, Lucas
    Malagon, Ignacio
    Buckens, Stan
    Custers, Jose A. E.
    Helder, Leonie
    Greco, Anna
    Joosten, Leo A. B.
    van Engelen, Baziel G. M.
    van Alfen, Nens
    Riazi, Sheila
    Treves, Susan
    Jungbluth, Heinz
    Snoeck, Marc M. J.
    Voermans, Nicol C.
    MEDICINE, 2021, 100 (33)
  • [10] RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction
    Kruijt, Nick
    Van den Bersselaar, Luuk
    Snoeck, Marc
    Kramers, Kees
    Riazi, Sheila
    Bongers, Coen
    Treves, Susan
    Jungbluth, Heinz
    Voermans, Nicol
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (01) : 2 - 14
12345